Brief: Grifols Gets FDA Approval To Start Phase 2 Trial With Immunoglobulin Eye Drops
21/05/2025 11:12
May 21 (Reuters) - Grifols SA GRLS.MC: GETS FDA APPROVAL TO START PHASE 2 TRIAL WITH IMMUNOGLOBULIN EYE DROP FOR DRY EYE DISEASE STUDY TO START IN Q3 Further company coverage: GRLS.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Grifols
See all newsSpanish stocks - Factors to watch on Nov 3
Brief: Grifols Approves Interim Dividend Of €0.15/Shr Payable On Dec 4
Brief: Grifols Q3 Group Profit €162 Mln
Refile: Grifols says Canada plasma license suspension has no impact on ongoing operations
Brief: Health Canada Suspends Licence Of Grifols Site In Winnipeg - Globe And Mail